These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 17761976)

  • 1. Nuclear factor-kB tumor expression predicts response and survival in irinotecan-refractory metastatic colorectal cancer treated with cetuximab-irinotecan therapy.
    Scartozzi M; Bearzi I; Pierantoni C; Mandolesi A; Loupakis F; Zaniboni A; Catalano V; Quadri A; Zorzi F; Berardi R; Biscotti T; Labianca R; Falcone A; Cascinu S
    J Clin Oncol; 2007 Sep; 25(25):3930-5. PubMed ID: 17761976
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.
    Cunningham D; Humblet Y; Siena S; Khayat D; Bleiberg H; Santoro A; Bets D; Mueser M; Harstrick A; Verslype C; Chau I; Van Cutsem E
    N Engl J Med; 2004 Jul; 351(4):337-45. PubMed ID: 15269313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of cetuximab/irinotecan in chemotherapy-refractory metastatic colorectal adenocarcinomas: a clinical practice setting, multicenter experience.
    Gebbia V; Del Prete S; Borsellino N; Ferraù F; Tralongo P; Verderame F; Leonardi V; Capasso E; Maiello E; Bordonaro R; Stinco S; Agostara B; Barone C
    Clin Colorectal Cancer; 2006 Mar; 5(6):422-8. PubMed ID: 16635281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insulin-like growth factor 1 expression correlates with clinical outcome in K-RAS wild type colorectal cancer patients treated with cetuximab and irinotecan.
    Scartozzi M; Mandolesi A; Giampieri R; Pierantoni C; Loupakis F; Zaniboni A; Galizia E; Giustini L; Silva RR; Bisonni R; Berardi R; Biagetti S; Menzo S; Falcone A; Bearzi I; Cascinu S
    Int J Cancer; 2010 Oct; 127(8):1941-7. PubMed ID: 20099280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of HER-3, insulin growth factor-1, nuclear factor-kB and epidermal growth factor receptor gene copy number in the prediction of clinical outcome for K-RAS wild-type colorectal cancer patients receiving irinotecan-cetuximab.
    Scartozzi M; Giampieri R; Maccaroni E; Mandolesi A; Giustini L; Silva R; Zaniboni A; Biscotti T; Biagetti S; Galizia E; Loupakis F; Falcone A; Bearzi I; Cascinu S
    Ann Oncol; 2012 Jul; 23(7):1706-12. PubMed ID: 22112971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multicenter Phase II study of cetuximab plus irinotecan in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin and fluoropyrimidines.
    Tahara M; Shirao K; Boku N; Yamaguchi K; Komatsu Y; Inaba Y; Arai T; Mizunuma N; Satoh T; Takiuchi H; Nishina T; Sakata Y
    Jpn J Clin Oncol; 2008 Nov; 38(11):762-9. PubMed ID: 18836202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of baseline clinical predictive factors of response to cetuximab-irinotecan in patients with irinotecan-refractory metastatic colorectal cancer.
    Hebbar M; Di Fioré F; Conroy T; Giraud C; Gasnault L; Fournier C; Péreira R; Bouché O; Fournier P; Deligny N; Joly JP; Maes P; Rad E; Michel P; Adenis A
    Oncology; 2007; 73(3-4):185-91. PubMed ID: 18418011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating VEGF reduction, response and outcome in advanced colorectal cancer patients treated with cetuximab plus irinotecan.
    Vincenzi B; Santini D; Russo A; Gavasci M; Battistoni F; Dicuonzo G; Rocci L; Rosaria VM; Gebbia N; Tonini G
    Pharmacogenomics; 2007 Apr; 8(4):319-27. PubMed ID: 17391070
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study.
    Saltz LB; Lenz HJ; Kindler HL; Hochster HS; Wadler S; Hoff PM; Kemeny NE; Hollywood EM; Gonen M; Quinones M; Morse M; Chen HX
    J Clin Oncol; 2007 Oct; 25(29):4557-61. PubMed ID: 17876013
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidermal growth factor receptor expression discrepancies in metastatic colorectal cancer patients treated with cetuximab plus irinotecan-based chemotherapy refractory to irinotecan and oxaliplatin.
    Han HS; Chang HJ; Hong YS; Kim SY; Lee KS; Jung KH
    Dis Colon Rectum; 2009 Jun; 52(6):1144-51; discussion 1152-3. PubMed ID: 19581859
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer.
    Sobrero AF; Maurel J; Fehrenbacher L; Scheithauer W; Abubakr YA; Lutz MP; Vega-Villegas ME; Eng C; Steinhauer EU; Prausova J; Lenz HJ; Borg C; Middleton G; Kröning H; Luppi G; Kisker O; Zubel A; Langer C; Kopit J; Burris HA
    J Clin Oncol; 2008 May; 26(14):2311-9. PubMed ID: 18390971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation between the response to cetuximab alone or in combination with irinotecan and the activated/phosphorylated epidermal growth factor receptor in metastatic colorectal cancer.
    Personeni N; Hendlisz A; Gallez J; Galdon MG; Larsimont D; Van Laethem JL; Nagy N; Barette M; Paesmans M; Cardoso F; Bleiberg H
    Semin Oncol; 2005 Dec; 32(6 Suppl 9):S59-62. PubMed ID: 16399434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase II study of cetuximab/irinotecan in patients with heavily pretreated metastatic colorectal cancer: predictive value of early specific toxicities.
    Gamucci T; Nelli F; Cianci G; Grassi G; Moscetti L; Sperduti I; Zeuli M; Cortesi E; D'Auria G; Pollera CF
    Clin Colorectal Cancer; 2008 Jul; 7(4):273-9. PubMed ID: 18650196
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of irinotecan and cetuximab given every 2 weeks as second-line therapy for advanced colorectal cancer.
    Carneiro BA; Ramanathan RK; Fakih MG; Krishnamurthi SS; Lembersky BC; Stoller RG; Lancaster SL; Pinkerton RA; Crandall TL; Schmotzer AR; Potter DM; Bahary N
    Clin Colorectal Cancer; 2012 Mar; 11(1):53-9. PubMed ID: 21813336
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Cetuximab and irinotecan for the treatment of metastatic colorectal cancer--pilot results from Masaryk Memorial Cancer Institute].
    Nēmecek R; Kocáková I; Kocák I; Svoboda M; Lakomý R; Poprach A; Vyskocil J; Vyzula R
    Klin Onkol; 2009; 22(1):27-33. PubMed ID: 19534437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer.
    Graziano F; Ruzzo A; Loupakis F; Canestrari E; Santini D; Catalano V; Bisonni R; Torresi U; Floriani I; Schiavon G; Andreoni F; Maltese P; Rulli E; Humar B; Falcone A; Giustini L; Tonini G; Fontana A; Masi G; Magnani M
    J Clin Oncol; 2008 Mar; 26(9):1427-34. PubMed ID: 18349392
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of HER-3 expression in the prediction of clinical outcome for advanced colorectal cancer patients receiving irinotecan and cetuximab.
    Scartozzi M; Mandolesi A; Giampieri R; Bittoni A; Pierantoni C; Zaniboni A; Galizia E; Giustini L; Silva RR; Bisonni R; Berardi R; Biscotti T; Biagetti S; Bearzi I; Cascinu S
    Oncologist; 2011; 16(1):53-60. PubMed ID: 21212430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early magnesium reduction in advanced colorectal cancer patients treated with cetuximab plus irinotecan as predictive factor of efficacy and outcome.
    Vincenzi B; Santini D; Galluzzo S; Russo A; Fulfaro F; Silletta M; Battistoni F; Rocci L; Zobel BB; Adamo V; Dicuonzo G; Tonini G
    Clin Cancer Res; 2008 Jul; 14(13):4219-24. PubMed ID: 18594003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integration of novel agents in the treatment of colorectal cancer.
    Iqbal S; Lenz HJ
    Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S32-9. PubMed ID: 15309512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cetuximab Plus irinotecan in pretreated metastatic colorectal cancer progressing on irinotecan: the LABEL study.
    Buzaid AC; Mathias Cde C; Perazzo F; Simon SD; Fein L; Hidalgo J; Murad AM; Esser R; Senger S; Lerzo G
    Clin Colorectal Cancer; 2010 Dec; 9(5):282-9. PubMed ID: 21208842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.